8-K: Health In Tech Reports Q3 2026 Results, Sees Revenue Decline

Health In Tech announced its third quarter 2026 financial results, reporting a decrease in revenue and an increase in net loss, alongside a revised full-year revenue outlook.

Summary

• Health In Tech reported Q3 2026 revenue of $6.6 million, down from $8.5 million in Q3 2025. Nine-month 2026 revenue was $23.4 million, compared to $25.8 million in the prior year.
• The company reported a net loss of $7.1 million for Q3 2026, or $(0.11) per diluted share, including a $5.3 million provision for credit losses. This compares to a net income of $0.5 million in Q3 2025.
• Nine-month 2026 net loss was $11.2 million, or $(0.18) per diluted share, with a $6.1 million provision for credit losses, compared to a net income of $1.6 million in the prior year.
• Adjusted EBITDA was $(3.9) million for Q3 2026 and $(6.6) million for the first nine months of 2026.
• Distribution partners grew 15.9% year-over-year to 984 as of September 30, 2026.
• Contracted Revenue for the first nine months of 2026 totaled $32.7 million, with $24.4 million recognized as GAAP revenue.
• Pipeline Revenue as of October 30, 2026, was $156.4 million, with an expected conversion rate of 3% to 7%.
• The company revised its full-year 2026 revenue outlook to approximately $30 million, which is modestly below 2025 revenue, due to delayed commencement of certain new policies.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to declining revenues, increased net losses, and a revised lower revenue outlook, despite growth in distribution partners.

Positives

• Distribution partners grew 15.9% year-over-year to 984 as of September 30, 2026.
• Contracted Revenue for the first nine months of 2026 totaled $32.7 million.
• Pipeline Revenue as of October 30, 2026, was $156.4 million, indicating potential future revenue.
• Launched HitRix, an AI-powered marketplace for large-group self-funded stop-loss insurance, in September 2026.
• Secured the first client for the Three-Year Rate Stabilization Program.
• Appointed Sanjay Shrestha as CEO with extensive experience in public-company leadership and capital markets.
• Elected Tim Cortes to the Board of Directors, bringing technology and engineering leadership experience.

Negatives

• Q3 2026 revenue was $6.6 million, a decrease from $8.5 million in Q3 2025.
• Nine-month 2026 revenue was $23.4 million, down from $25.8 million in the prior year.
• Q3 2026 net loss was $7.1 million, compared to a net income of $0.5 million in Q3 2025.
• Nine-month 2026 net loss was $11.2 million, compared to a net income of $1.6 million in the prior year.
• Significant provision for credit losses: $5.3 million in Q3 2026 and $6.1 million for the nine months ended September 30, 2026.
• Adjusted EBITDA was negative for both Q3 2026 ($(3.9) million) and the first nine months of 2026 ($(6.6) million).
• Revised full-year 2026 revenue outlook to approximately $30 million, modestly below 2025 revenue.
• Cash balance was $10.1 million as of September 30, 2026, which may be a concern given the net losses.

Risks

• The company's ability to regain and maintain compliance with Nasdaq continued listing requirements.
• Risks related to the leadership transition, including integrating new management and retaining key personnel.
• Ability to identify, negotiate, finance, complete, and integrate acquisitions or strategic transactions.
• Ability to obtain funding for operations and enhance systems and service offerings.
• Success, cost, and timing of product development activities.
• Ability to attract and retain key personnel and qualified employees.
• Impact of competition and innovation by competitors in the industry.
• Risks related to cybersecurity incidents or other network disruptions.

Future Outlook

The company expects to recognize $6.1 million of Contracted Revenue in Q4 2026 and $2.2 million in 2027. The full-year 2026 revenue outlook has been revised to approximately $30 million, which is modestly below 2025 revenue, due to delayed policy commencements. The focus for 2027 will shift towards commercialization, disciplined execution, and generating measurable returns from investments. A more detailed update on strategic priorities is expected with the full-year 2026 results.

Management Comments

• "It is a privilege to lead Health In Tech into its next chapter, and I want to thank Tim Johnson, our founder and Executive Chairman, and the Board for their confidence."
• "Throughout my career, I have focused on scaling businesses, developing growth strategies, and leveraging capital markets to support long-term value creation."
• "Having previously served as a director on Health In Techs Board and then as a strategic advisor to the Board, I have gained valuable perspective on the Companys technology foundation, business model, and market opportunities. I look forward to bringing my experience and a fresh perspective to help unlock the next phase of growth."
• "Our immediate priority is to improve quote-to-bind conversion, translate marketplace activity into placed policies and recognized revenue, and strengthen overall financial performance."
• "As we move into 2027, our focus will increasingly shift toward commercialization, disciplined execution, and generating measurable returns from these investments."
• "Our objective is to transform the strong foundation we believe Health In Tech has built into a more scalable, commercially successful, and financially disciplined business that creates sustainable long-term shareholder value."

Industry Context

StockSavvy.ai notes that Health In Tech operates in the InsurTech sector, which is characterized by rapid technological adoption, particularly AI, and a focus on streamlining insurance processes. The company's reported revenue decline and increased losses, despite partner growth, suggest challenges in converting market activity into recognized revenue, a common hurdle for growth-stage InsurTech firms navigating complex regulatory and sales cycles.

Management Changes

Stakeholder Impact

• Shareholders may be concerned by the declining revenues, increased net losses, and revised lower revenue outlook, potentially impacting stock price.
• Employees may face uncertainty due to the company's financial performance and the strategic review initiated by the new CEO.
• Distribution partners and clients may be affected by the company's focus on improving conversion rates and operational efficiency.

Next Steps

• Improve quote-to-bind conversion rates.
• Translate marketplace activity into placed policies and recognized revenue.
• Strengthen overall financial performance.
• Focus on commercialization and disciplined execution in 2027.
• Generate measurable returns from investments made in distribution, technology, and product development.
• Evaluate strategic acquisitions, partnerships, and other expansion opportunities.
• Provide a more detailed update on strategic priorities when reporting full-year 2026 results.

Key Dates

Recommendation

The filing indicates a worsening financial trend with declining revenues, increased net losses, and a reduced revenue outlook. While there are strategic initiatives and partner growth, the core financial performance is deteriorating, and the company faces challenges in converting its pipeline into revenue. The significant provision for credit losses also raises concerns about asset quality. The appointment of a new CEO with a focus on scaling and financial discipline is a positive, but the immediate financial results warrant caution.

Keywords

InsurTech, AI-enabled, Health Insurance, Stop-loss Insurance, Self-funded Health Plans, Distribution Partners, Revenue Outlook, Financial Results